Asco 2022 – Enhertu asks, how low can you go?
Another strong readout could redefine how Her2-negative breast cancer is treated, though a declared victory in triple-negatives is less clear.
The patent winter is coming
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
Clovis equity investors overlook two elephants
Rubraca has scored in an all-comers, first-line ovarian cancer maintenance setting, but Clovis has bigger problems.
What’s next for relatlimab?
The Lag3 inhibitor is now approved in melanoma, but Bristol looks unlikely to stop there in its search for a safer Yervoy.
Medicare’s new devices
A handful of medtechs will benefit from new reimbursement pathways – but others have been denied the chance.
